Figure 7
Immune modulations in tolerant recipients after MyD88, TRIF and mTOR siRNA treatment.
(A,B) Tol-DC generated in tolerant recipients. Mice were treated and transplanted with allografts as described in Fig. 5. Splenic cells were isolated from BALB/c recipients at the time of rejection or 100 days post transplantation. Splenic cells were stained with antibodies against CD11C, CD40, CD86 and PD-L1. Flow cytometry was performed to determine the splenic DCs population by first gating CD11C+ cells and then subsequently analyzing the CD40, CD86 and PD-L1 expression of recipient mice (A) and the average expression of CD40, CD86 and PD-L1 (B) (n = 6, *P < 0.05 vs control group). (C) DCs from long-term survival recipients attenuate alloimmune stimulatory capacity. Mice were treated and transplanted with allografts as described in Fig. 3. Splenic DCs were isolated from BALB/c recipients at the time of rejection or 100 days post transplantation. DCs were co-cultured with allogeneic T cells from naïve C57BL/6 mice at different ratios. After 48 h, [3H]-thymidine was added to the coculture for another 18 h and its incorporation was measured as an indicator of T cell proliferation. Data shown are mean ± SEM (n = 6, *P < 0.05 vs control group).
